Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 44, Issue 7, Pages 457-473Publisher
CELL PRESS
DOI: 10.1016/j.tips.2023.04.004
Keywords
-
Categories
Ask authors/readers for more resources
Metformin, the most prescribed drug for T2DM, has both liver and gut as important targets for its glucose-lowering effect through new mechanisms of action. The understanding of metformin's action in these organs and its relevance in patients remains a challenge for current and future research, potentially impacting T2DM drug development.
Metformin is the most prescribed drug for the treatment of type 2 diabetes mellitus (T2DM), but its mechanism of action has not yet been completely eluci-dated. Classically, the liver has been considered the major site of action of met-formin. However, over the past few years, advances have unveiled the gut as an additional important target of metformin, which contributes to its glucose-lowering effect through new mechanisms of action. A better understanding of the mechanistic details of metformin action in the gut and the liver and its rele-vance in patients remains the challenge of present and future research and may impact drug development for the treatment of T2DM. Here, we offer a critical analysis of the current status of metformin-driven multiorgan glucose-lowering effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available